We hypothesized that stronger HMGCR expression was associated with markers of good prognosis and prolonged disease-free survival (DFS), as well as a better response to tamoxifen, in this population-based unselected cohort of primary breast cancer patients. The gene discussed is HMGCR; the disease is breast carcinoma.